Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens

Novel polymyxin derivatives are less cytotoxic than polymyxin B to renal proximal tubular cells

(2012) Marie-Paule Mingeot-Leclercq et al.   PEPTIDES

Impact of healthcare-associated acquisition on community-onset Gram-negative bloodstream infection: a population-based study

(2011) M. N. Al-Hasan et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09)

(2011) A. C. Gales et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Polymyxins and their novel derivatives

(2010) Martti Vaara   CURRENT OPINION IN MICROBIOLOGY

Novel polymyxin derivatives are effective in treating experimental Escherichia coli peritoneal infection in mice

(2010) C. Vingsbo Lundberg et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Susceptibility of carbapenemase-producing strains of Klebsiella pneumoniae and Escherichia coli to the direct antibacterial activity of NAB739 and to the synergistic activity of NAB7061 with rifampicin and clarithromycin

(2010) M. Vaara et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Epidemiology, microbiology and outcomes of healthcare-associated and community-acquired bacteremia: A multicenter cohort study

(2010) Marin H. Kollef et al.   JOURNAL OF INFECTION

Nephrotoxicity of Colistin: New Insight into an Old Antibiotic

(2009) Matthew E. Falagas et al.   CLINICAL INFECTIOUS DISEASES

Novel Polymyxin Derivatives Carrying Only Three Positive Charges Are Effective Antibacterial Agents

(2008) M. Vaara et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY